Literature DB >> 8190037

Autoimmune myelofibrosis. A steroid-responsive cause of bone marrow fibrosis associated with systemic lupus erythematosus.

R L Paquette1, A Meshkinpour, P J Rosen.   

Abstract

Autoimmune myelofibrosis is an uncommon disorder in which patients present with anemia and thrombocytopenia in conjunction with limited clinical manifestations of autoimmune disease or an exacerbation of previously established SLE. The presence of leukoerythroblastosis in a patient with SLE may suggest the presence of myelofibrosis. Conversely, the absence of splenomegaly in a patient with presumed idiopathic myelofibrosis may suggest an autoimmune etiology. Patients with autoimmune myelofibrosis universally have a positive ANA test and frequently have either elevated anti-DNA titers or a positive LE cell preparation. Because physical manifestations of autoimmune disease may not be evident at presentation, all patients found to have myelofibrosis should have an ANA test. Peripheral blood cytopenias in autoimmune myelofibrosis frequently respond to glucocorticoids but regression of bone marrow fibrosis may be incomplete. Hematologic response to treatment parallels that of the associated autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8190037

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  17 in total

Review 1.  Anemia of Central Origin.

Authors:  Kazusa Ishii; Neal S Young
Journal:  Semin Hematol       Date:  2015-07-09       Impact factor: 3.851

Review 2.  Lessons learned from bone marrow failure in systemic lupus erythematosus: Case reports and review of the literature.

Authors:  Erik Anderson; Bhakti Shah; Anne Davidson; Richard Furie
Journal:  Semin Arthritis Rheum       Date:  2017-12-08       Impact factor: 5.532

3.  A rare cause of cytopenia in a patient with systemic lupus erythematosus: Autoimmune myelofibrosis.

Authors:  Döndü Üsküdar Cansu; Hava Üsküdar Teke; Cengiz Korkmaz
Journal:  Eur J Rheumatol       Date:  2017-03-01

Review 4.  An immune dysregulation in MPN.

Authors:  Giovanni Barosi
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

5.  Primary autoimmune myelofibrosis: a case report and review of the literature.

Authors:  Yasmin Abaza; C Cameron Yin; Carlos E Bueso-Ramos; Sa A Wang; Srdan Verstovsek
Journal:  Int J Hematol       Date:  2016-11-09       Impact factor: 2.490

6.  Autoimmune myelofibrosis: a rare haematological involvement in systemic lupus erythematosus.

Authors:  Nabil Belfeki; Gopinath Shankarasivam; Damienne Declerck; Sylvain Diamantis
Journal:  BMJ Case Rep       Date:  2019-01-14

7.  Autoimmune Myelofibrosis in Systemic Lupus Erythematosus Report of Two Cases and Review of the Literature.

Authors:  Prasad R Koduri; Mohammad Parvez; Sashidhar Kaza; S Vanajakshi
Journal:  Indian J Hematol Blood Transfus       Date:  2015-02-15       Impact factor: 0.900

8.  Primary autoimmune myelofibrosis in a 36-year-old patient presenting with isolated extreme anemia.

Authors:  Fabio P S Santos; Sergej N Konoplev; Huifang Lu; Srdan Verstovsek
Journal:  Leuk Res       Date:  2009-09-11       Impact factor: 3.156

9.  Idiopathic Acquired Osteosclerosis in a Middle-Aged Woman With Systemic Lupus Erythematosus.

Authors:  Núria Guañabens; Steven Mumm; Laia Gifre; Silvia Ruiz-Gaspà; Jennifer L Demertzis; Marina Stolina; Deborah V Novack; Michael P Whyte
Journal:  J Bone Miner Res       Date:  2016-05-09       Impact factor: 6.741

10.  Congenital macrothrombocytopenia with focal myelofibrosis due to mutations in human G6b-B is rescued in humanized mice.

Authors:  Inga Hofmann; Mitchell J Geer; Timo Vögtle; Andrew Crispin; Dean R Campagna; Alastair Barr; Monica L Calicchio; Silke Heising; Johanna P van Geffen; Marijke J E Kuijpers; Johan W M Heemskerk; Johannes A Eble; Klaus Schmitz-Abe; Esther A Obeng; Michael Douglas; Kathleen Freson; Corinne Pondarré; Rémi Favier; Gavin E Jarvis; Kyriacos Markianos; Ernest Turro; Willem H Ouwehand; Alexandra Mazharian; Mark D Fleming; Yotis A Senis
Journal:  Blood       Date:  2018-06-13       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.